透析前项目入组后第一年eGFR变异性与CKD不良结局
这项前瞻性队列研究纳入5092例接受多学科管理的CKD患者,分析透析前项目入组后第一年eGFR变异性和纵向变化与ESRD、ACS及死亡风险的关系。研究发现第一年eGFR变异性和纵向变化指标均与ESRD、ACS和死亡风险独立相关,结合两者的风险矩阵有助于CKD风险分层。
要点
- 第一年eGFR变异性和纵向变化是CKD进展至ESRD、ACS和死亡的预后因素。
- eGFR-CV最高四分位合并其他指标最严重下降四分位的患者所有结局风险最高。
- 风险矩阵可整合第一年eGFR变异性和纵向变化用于CKD风险特征描述。
核心结论
- 透析前项目入组后第一年eGFR总体变异性和纵向变化是CKD患者进展至ESRD、ACS和死亡的关键预后因素。
研究设计与样本
- 前瞻性队列研究,纳入2003至2015年间接受多学科管理的5092例CKD患者,随访期间确认ESRD、ACS和死亡事件。
主要发现
- 随访期间发生786例ESRD、292例ACS和410例死亡事件。
- 多变量Cox回归中,eGFR-CV、eGFR-PC、eGFR-AD、eGFR-slope、eGFR-AUC每单位变化的完全校正ESRD风险HR分别为1.03(95%CI 1.02-1.04)、1.04(1.03-1.04)、1.16(1.14-1.18)、1.16(1.14-1.17)、1.04(1.03-1.04)。
- 比较极端四分位与参考四分位,eGFR-CV、eGFR-PC、eGFR-AD、eGFR-slope、eGFR-AUC的校正ESRD风险HR分别为2.67(95%CI 2.11-3.38)、8.34(6.33-10.98)、19.08(11.89-30.62)、13.08(8.32-20.55)、6.35(4.96-8.13)。
- 对ACS和死亡风险观察到类似方向的效果。
- 在2×2风险矩阵中,eGFR-CV最高四分位且合并其他任一纵向eGFR变化指标最严重下降四分位的患者所有结局风险最高。
临床怎么用
- 在CKD管理中可结合第一年eGFR变异性和纵向变化指标构建风险矩阵,识别高风险患者。
局限性
- 需要随机对照试验来确认可比的基线eGFR动态变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Scarce evidence associates the first-year estimated glomerular filtration rate (eGFR) variability and longitudinal change scales concomitantly to the risk of developing end-stage renal disease (ESRD), acute coronary syndrome (ACS) and death following pre-ESRD program enrollment in chronic kidney disease (CKD). METHODS: We conducted a prospective cohort study of 5092 CKD patients receiving multidisciplinary care between 2003 and 2015 with careful ascertainment of ESRD, ACS and death during the follow-up. First-year eGFR variability and longitudinal change scales that were based on all first-year eGFR measurements included coefficient of variation of eGFR (eGFR-CV), percent change (eGFR-PC), absolute difference (eGFR-AD), slope (eGFR-slope) and area under the curve (AUC). RESULTS: A total of 786 incident ESRD, 292 ACS and 410 death events occurred during the follow-up. In the multiple Cox regression, the fully adjusted hazard ratios (HRs) of progression to ESRD for each unit change in eGFR-CV, eGFR-PC, eGFR-AD, eGFR-slope, eGFR-AUC were 1.03 [95% confidence interval (CI) 1.02-1.04], 1.04 (1.03-1.04), 1.16 (1.14-1.18), 1.16 (1.14-1.17) and 1.04 (1.03-1.04), respectively. The adjusted HRs for incident ESRD comparing the extreme with the reference quartiles of eGFR-CV, eGFR-PC, eGFR-AD, eGFR-slope and eGFR-AUC were 2.67 (95% CI 2.11-3.38), 8.34 (6.33-10.98), 19.08 (11.89-30.62), 13.08 (8.32-20.55) and 6.35 (4.96-8.13), respectively. Similar direction of the effects on the risk of developing ACS and mortality was observed. In the 2 × 2 risk matrices, patients with the highest quartile of eGFR-CV and concomitantly with the most severely declining quartiles of any other longitudinal eGFR change scale had the highest risk of all outcomes. CONCLUSIONS: The dynamics of eGFR changes, both overall variability and longitudinal changes, over the first year following pre-ESRD program enrollment are crucial prognostic factors for the risk of progression to ESRD, ACS and deaths among patients with CKD. A risk matrix combining the first-year eGFR variability and longitudinal change scales following pre-ESRD enrollment is a novel approach for risk characterization in CKD care. Randomized trials in CKD may be required to ascertain comparable baseline eGFR dynamics.
引用
- Tsai CW, Huang HC, Chiang HY, et al. First-year estimated glomerular filtration rate variability after pre-end-stage renal disease program enrollment and adverse outcomes of chronic kidney disease. Nephrol Dial Transplant. 2019. PMID: 29982714. doi:10.1093/ndt/gfy200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。